|
|
|
|
Cordex Completes Production of ATPace Clinical Trial Material
Cordex Pharma, Inc.(OTC:CDXP) (BULLETIN BOARD: CDXP) announced today that it has successfully completed the production of the ATPace(TM) clinical trial material (CTM) in preparation for planned pivotal clinical trials. The protocol of...
|
|
|
Cordex Completes Production Of ATPace Clinical Trial Material
Clinical trials for the acute treatment of patients presenting with paroxysmal supraventricular tachycardia (PSVT) Cordex has completed the production of the ATPace clinical trial material (CTM), in preparation for planned pivotal...
|
|
|
Cordex Pharma's ATPace Drug
Cordex Pharma said today it successfully completed the production of the ATPace clinical trial material (CTM) in preparation for planned pivotal clinical trials.ATPace is a novel, proprietary, stable, injectable formulation of adenosine 5...
Diagnostic & Invasive Cardiology:
Jun 29 2009 11:55PM
Matching: tachycardia ventricular
|
Find similar documents
|
|
|
|
Cordex Pharma Completes Production of ATPace(TM) Clinical Trial Material
LA JOLLA, Calif., June 29 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc.announced today that it has successfully completed the production of the ATPace(TM) clinical trial material (CTM) in preparation for planned pivotal clinical trials.
|
|
|
Cordex Completes Production of ATPace(TM) Clinical Trial Material
LA JOLLA, Calif., June 29 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc.announced today that it has successfully completed the production of the ATPace(TM) clinical trial material (CTM) in preparation for planned pivotal clinical trials.
|
|
|
Cordex Completes Production of ATPace(TM) Clinical Trial Material
LA JOLLA, Calif., June 29 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc.announced today that it has successfully completed the production of the ATPace(TM) clinical trial material (CTM) in preparation for planned pivotal clinical trials.
|
|
|
Cordex Completes Production of ATPace(TM) Clinical Trial Material
LA JOLLA, Calif.ATPace(TM) is a novel, proprietary, stable, injectable formulation of adenosine 5'-triphosphate (ATP) under development as a therapeutic and diagnostic drug for the management of cardiac arrhythmias. A stable liquid...
|
|
|
Cordex Completes Production of ATPace(TM) Clinical Trial Material
LA JOLLA, Calif., June 29 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc.ATPace(TM) is a novel, proprietary, stable, injectable formulation of adenosine 5'-triphosphate (ATP) under development as a therapeutic and diagnostic drug for the...
|
|
|
Cordex Completes Production of ATPace(TM) Clinical Trial Material
LA JOLLA, Calif., June 29 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today that it has successfully completed the production of the ATPace(TM) clinical trial material (CTM) in preparation for...
|
|
|
Idebenone Well Tolerated in Patients With Friedreich's Ataxia: Presented at ENS
my personal edition> neurologic other > news E-Mail this DGDispatch to a colleague DGDispatch MILAN, Italy -- June 25, 2009 -- In patients with the rare autosomal recessive disorder Friedreich's ataxia (FRDA), idebenone is...
|
|
|
Sorin Group Announces European Market Release and First Implant of Its New-Generation Dual Chamber Implantable
Sorin Group, (MIL:SRN) (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today the commercial market release and first implant of its new generation PARADYM„...
|
|
|
Electrocardiographic Alterations During Endosseous Implant Placement Performed with Local Anesthetic Agents
(Click the title below to leave the MDLinx Network and go to the Journal's Website) The International Journal of Oral & Maxillofacial Implants, 06/23/09 Print Save in My Library Free Abstract Romano MM et al.- Dental implant...
|
|
|
New Onset A-Fib Tied to Adverse Outcomes After PCI
New onset atrial fibrillation (A-fib) that develops in patients undergoing percutaneous coronary intervention (PCI) is independently associated with increased 90-day mortality and other adverse events, according to a paper published online...
|
|
|
Cordex Receives Special Protocol Assessment Approval from FDA for ATPace
Cordex Pharma, Inc.announced that the U.S. Food and Drug Administration (FDA) has approved the design of pivotal, Phase 2b/3 clinical trials evaluating its lead product ATPace as an antiarrhythmic drug for the acute treatment of...
|
|
|
NHL prospects screened for heart disease
TORONTO - NHL Combine is an annual event giving hockey insiders and media a first-hand look at the future stars of tomorrow.The week-long affair is designed to test an athletes' physical health prior to the draft. They endure rigorous...
|
|
|
Atrial Tachycardias Encountered in the Context of Catheter Ablation for Atrial Fibrillation Part II: Mapping a
_ Atrial Tachycardias Encountered in the Context of Catheter Ablation for Atrial Fibrillation Part II: Mapping a.
|
|
|
Acebutolol: ventricular tachycardia
_ Acebutolol: ventricular tachycardia.
|
|
|
Recurrence of ventricular arrhythmias in ischaemic secondary prevention implantable cardioverter defibrillator
During follow-up, 100 (22%) pts died and ICD therapy in 216 (47%) pts Fast, potentially life-threatening ventricular arrhythmia in 138 (30%) pts On multivariate analysis, history of atrial fibrillation or flutter (AF), ventricular...
|
|
|
FDA Reverses Earlier Decision, Approves Schizophrenia Drug
2009 American Psychiatric Association Jun Yan The new antipsychotic medication has pharmacological and clinical profiles similar to those of other second-generation drugs on the market and appears to carry comparable risks.After being...
|
|
|
Gastroparesis and Diabetes
Gastroparesis is seen in patients with both type 1 and type 2 diabetes and means that the stomach takes too long to empty its contents.There are many types of diabetic autonomic neuropathy, including resting tachycardia, exercise...
|
|
|
Cordex Receives Special Protocol Assessment Approval From FDA For ATPace(TM)
Cordex Pharma, Inc.(OTC Bulletin Board: CDXP) announced that the U.S. Food and Drug Administration (FDA) has approved the design of pivotal, Phase 2b/3 clinical trials evaluating its lead product ATPace(TM) as an antiarrhytmic drug for...
|
|
|
FDA Gives Green Light for ATPace Drug Pivotal Clinical Trial
- Cordex Pharma Inc.said today the FDA cleared the design of pivotal, phase 2b/3 clinical trials evaluating its lead product ATPace as an antiarrhytmic drug for the acute treatment of patients with paroxysmal supraventricular ...
|
|
|
Cordex Receives Special Protocol Assessment Approval from FDA for ATPace(TM)
LA JOLLA, Calif., June 2 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc.(OTC Bulletin Board: CDXP) announced today that the U.S. Food and Drug Administration (FDA) has approved the design of pivotal, Phase 2b/3 clinical trials evaluating...
|
|
|
Can MannKind deliver on deal expectations?; Exelixis shares slide on disappointing cancer data;
> Analysts are divided over MannKind's prospects for gaining a rich partnership deal on its experimental inhaled insulin therapy.MannKind's shares have tripled in price in anticipation of a deal, but some of the analysts are distinctly...
|
|
|
Cordex Pharma Receives Special Protocol Assessment Approval from FDA for ATPace(TM)
LA JOLLA, Calif., June 2 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc.(OTC Bulletin Board: CDXP - News) announced today that the U.S. Food and Drug Administration (FDA) has approved the design of pivotal, Phase 2b/3 clinical trials...
|
